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Abstract
Improving the effectiveness of preclinical predictions of human drug responses is critical to 
reducing costly failures in clinical trials. Recent advances in cell biology, microfabrication and 
microfluidics have enabled the development of microengineered models of the functional units of 
human organs — known as organs-on-chips — that could provide the basis for preclinical assays 
with greater predictive power. Here, we examine the new opportunities for the application of 
organ-on-chip technologies in a range of areas in preclinical drug discovery, such as target 
identification and validation, target-based screening, and phenotypic screening. We also discuss 
emerging drug discovery opportunities enabled by organs-on-chips, as well as important 
challenges in realizing the full potential of this technology.
The pharmaceutical industry is facing unprecedented challenges owing to rising costs and 
the declining efficiency of drug research and development1,2. As drug failures in clinical 
trials are primarily due to the poor predictive power of existing preclinical models, the drug 
discovery community has identified the critical need for new testing approaches to generate 
reliable predictions of drug efficacy and safety in humans3–6.
Microengineered cell culture models could provide a solution to this unmet need. These 
models leverage cutting edge microfabrication and microfluidics technologies to control the 
cellular microenvironment with high spatiotemporal precision and to present a variety of 
extracellular cues to cultured cells in a physiologically relevant context7–10. The latest 
progress in this area has led to the development of novel microdevices, known collectively as 
organs-on-chips, that recapitulate the complex structure, microenvironment and 
physiological functionality of living human organs11–13.
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In this article, we provide a perspective on the breadth of new opportunities afforded by the 
integration of this emerging organ-on-chip technology with drug discovery and 
development. We first introduce the technological background and advantages of organs-on-
chips and then use examples drawn from recent studies to demonstrate how organ-on-chip 
technology has begun to tackle major technical challenges at the critical steps of 
conventional and emerging drug discovery processes in a cost-effective manner. Future 
directions and technical challenges for the field are also discussed.
Microphysiological organ models
Organs-on-chips are microengineered biomimetic systems that represent key functional units 
of living human organs. They often consist of transparent 3D polymeric microchannels lined 
by living human cells and replicate three important aspects of intact organs: the 3D 
microarchitecture defined by the spatial distribution of multiple tissue types; functional 
tissue–tissue interfaces; and complex organ-specific mechanical and biochemical 
microenvironments11,13–17. These systems could be used as specialized in vitro models that 
permit simulation, mechanistic investigation and pharmacological modulation of complex 
biological processes (TABLE 1).
In recent years, this biomimetic microsystems approach has been used to establish 
microengineered models that recapitulate the structural and functional complexity of human 
organs such as the liver, heart, lung, intestine, kidney, brain and bone11,18–20. A 
representative example is the lung-on-a-chip microdevice that reconstitutes the mechanically 
active alveolar–capillary barrier in the human lung13 (FIG. 1). This model is created in a 
compartmentalized 3D microfluidic system in which human alveolar epithelial cells are 
cultured in close apposition with human pulmonary microvascular endothelial cells on a thin 
porous elastomeric membrane to form a barrier tissue that resembles the in vivo alveolar–
capillary interface. This microfluidic cell culture system is integrated with a biologically 
inspired mechanical actuation system that uses computer-controlled negative pressure to 
cyclically stretch the alveolar–capillary barrier to mimic physiological breathing motions. 
Importantly, this device enables the reconstitution and visualization of complex, integrated, 
organ-level responses not normally observed in conventional cell culture models, such as 
recruitment and phagocytic activity of blood-borne immune cells in response to bacteria, 
inflammatory cytokines and environmental nanoparticulates13 (FIG. 1b). Moreover, the 
ability of this model to recapitulate the dynamic mechanical activity of the lung has led to 
the discovery of previously unexplained adverse effects of physiological breathing-induced 
mechanical forces on inflammatory and injury responses. For example, in nanotoxicology 
studies using silica nanoparticles that simulated air pollutants, the cyclic breathing motions 
in the lung-on-a-chip system substantially increased the endothelial expression of pro-
inflammatory adhesion molecules and the intracellular production of reactive oxygen 
species, indicating that physiological breathing promotes acute toxic responses to 
environmental particulates13. This biomimetic microdevice also revealed considerable 
increases in the translocation of nanoparticles from the alveolar airspace to the vascular 
compartment due to breathing-associated mechanical strain13.
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The same system was further engineered to model the development and progression of 
pulmonary oedema induced by toxicity of the anticancer drug interleukin-2 (IL-2)15 (FIG. 
1c). Specifically, clinically relevant concentrations of IL-2 administered into the 
microvascular channel led to continuous leakage of vascular fluid into the alveolar 
compartment and complete flooding of the airspace in time frames similar to those observed 
in humans. Based on the observation that these deleterious responses were greatly 
exacerbated by physiological mechanical stresses produced by breathing, this 
microengineered disease model also facilitated the identification of novel therapeutics that 
inhibited mechanotransduction pathways critical to compromised alveolar–capillary barrier 
function (this study is revisited in greater depth in the ‘Toxicity screening’ section below). 
Importantly, key findings in these studies were reproduced in whole mouse lung, 
demonstrating the capability of the lung-on-a-chip system to faithfully recapitulate and 
predict complex physiology and pathology in vivo15.
Comparison with conventional models
For the evaluation of drug efficacy and safety, organs-on-chips provide compelling 
advantages over other in vitro cell culture models. Although 2D culture models can provide 
large amounts of relatively inexpensive data, these models poorly represent complex 
pathophysiology in patients and require computational modelling and systems biology 
approaches to predict in vivo drug responses.
Biomimetic 3D tissue structures with physiological barrier function more accurately 
simulate delivery and penetration of drug compounds in vivo than do 2D cell monolayers in 
conventional culture models21 (TABLE 2). More importantly, these microengineered co-
culture models recapitulate the complex interactions between different types of cells in vivo 
that are mediated by various soluble and insoluble factors such as cytokines, nutrients, 
growth factors, hormones, the extracellular matrix and intercellular junctions, all of which 
can be controlled within the organ-on-a-chip20,22–24. Unlike 2D culture systems, organs-on-
chips can therefore reconstitute complex organ-level physiological functions, clinically 
relevant disease phenotypes and pharmacological responses that arise from structural and 
functional integration of multiple tissue types. This characteristic allows for more 
comprehensive and accurate predictions of complex drug responses in vivo. Fluid motions 
and cell culture substrates in organs-on-chips can also be controlled to reproduce various 
types of mechanical cues induced by physiological flow (for example, blood flow and 
interstitial flow) and tissue deformation (for example, breathing, peristalsis and heartbeat), 
including fluid shear stress, tension, compression and torque11,22–25.
Organs-on-chips also have advantages over current animal models. Although animal studies 
can emulate physiological complexity at the whole-organism level, animal surrogates of 
human diseases are now facing increased scrutiny and scepticism regarding their scientific 
validity and translatability to humans26,27. Recent systematic studies on the predictive value 
of animal models have demonstrated a poor correlation between animal data and human 
outcomes owing to substantial interspecies differences in key disease pathways and disease-
induced changes in gene expression profiles, highlighting the critical need for new 
approaches to model complex human-relevant conditions28,29.
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The optical transparency of organ-on-chip microdevices is another key advantage over 
animal models as it enables direct real-time visualization and quantitative high-resolution 
analysis of diverse biological processes in ways that have not been possible in animal 
models30. In addition, compartmentalized channel designs for co-culture in organs-on-chips 
(for example, upper and lower channels separated by a thin porous membrane) allow for 
independent fluidic access to different tissue types within a single device and parametric 
control of microenvironmental factors. Conditioned media can therefore be sampled from 
specific tissue types of interest to analyse their metabolites and other secretory products, 
which may aid in the identification and development of novel biomarkers for efficacy, 
toxicity or disease processes25,31.
Organs-on-chips could also reduce consumption of costly reagents including cells, culture 
media and drug compounds. Considering that animal studies typically require scale-up of 
compound production to generate adequate quantities for dosing, organs-on-chips could be 
used earlier in the drug discovery pipeline than animal models, whether to more robustly 
characterize investigative compounds or to bridge conventional 2D culture studies.
Target identification and validation
Organs-on-chips have the potential to serve as a new enabling platform to identify and 
validate the efficacy, safety and druggability of potential targets early in the pipeline to 
increase the likelihood of success in clinical trials. A good example of such an application is 
provided in the work of Song et al.32, whereby a microengineered model of vasculature was 
used to mechanistically examine chemokine-mediated interactions between circulating 
breast cancer cells and the microvascular endothelium (FIG. 2a). This microsystem 
consisted of an upper intravascular compartment and lower stromal chambers separated by a 
semi-porous membrane lined with human microvascular endothelial cells. The 
compartmentalized channel design permitted the recreation of physiological dynamic flow 
conditions and circulation of metastatic breast cancer cells in the vascular channel. This 
model also enabled site-specific basal stimulation and activation of the microfluidic 
endothelium by introducing chemokines into the lower chambers. Through quantitative 
analysis of cancer cell attachment to the endothelium and the levels of cell surface receptor 
expression, this system revealed that endothelial recruitment of breast cancer cells induced 
by CXC-chemokine ligand 12 (CXCL12), a chemokine involved in cancer metastasis, is 
mediated by the endothelial receptor CXCR4 and that this response is independent of the 
expression of CXCL12 receptors on circulating cancer cells. These findings demonstrated a 
previously unknown critical role of the vascular endothelium in the metastatic behaviour of 
circulating tumour cells. More importantly, the functionality of this model enabled the 
researchers to precisely control and manipulate a biological target and to analyse a 
functional outcome of target modulation, which led to the discovery that inhibition of 
CXCL12–CXCR4 binding on endothelial cells may be a valid therapeutic target for 
preventing cancer metastasis.
Researchers are now beginning to apply this type of approach to modelling 
pathophysiological situations of increasing complexity and clinical relevance. For instance, a 
microengineered 3D cell culture device has been created to establish an organ-specific 
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disease model that simulates complex interactions between circulating metastatic breast 
cancer cells, vascular endothelium and bone tissue to investigate the specificity of human 
breast cancer metastases to bone33 (FIG. 2b). To reconstitute the tissue–tissue interface 
between the endothelium and bone, this model used a lining of human umbilical vein 
endothelial cells in a microfluidic channel adjacent to a 3D collagen gel that contained bone 
cells differentiated from human bone marrow-derived mesenchymal stem cells. Cancer 
metastasis in this system was examined using high-resolution real-time microscopy to 
measure trans-endothelial migration of metastatic breast cancer cells circulating in the 
vascular channel and their subsequent migration deeper into the bone matrix. This analysis 
showed that the chemokine CXCL5 (produced by bone cells) and its receptor CXCR2 
(expressed by tumour cells) are major signalling mediators that govern the rate and extent of 
cancer cell extravasation and migration, indicating that CXCL5 and CXCR2 could be 
potential targets for therapeutic intervention.
As illustrated by these representative studies, the organ-on-chip microengineering approach 
could expand our fundamental knowledge of biological systems and enable more accurate 
validation of organ-specific and effective therapeutic targets. Other studies have used similar 
microengineering principles to investigate molecular mechanisms of immune cell–cancer 
cell crosstalk34, astrocyte–neuron interactions in an enzyme-mutant model of amyotrophic 
lateral sclerosis35, mitochondrial cardiomyopathy of Barth syndrome36 and biomechanical 
force-induced exacerbation of drug-induced toxicities in pulmonary oedema15.
Potential uses in drug screening
Organ-on-chip technology is being used to develop cost-effective in vitro models for hit-to-
lead and lead optimization that can more reliably predict the efficacy, toxicity and 
pharmacokinetics of drug compounds in humans, as well as for novel phenotypic screening 
assays, as described below.
Efficacy
Poor efficacy in clinical trials is caused by an absence of predicted therapeutic effects or the 
unexpected need to increase the dose to levels at which toxicity also becomes apparent. In 
these cases, the undesirable outcome results directly from the failure of existing methods to 
accurately predict in vivo drug efficacy before clinical trials. Human organ-on-a-chip models 
are well suited to have an instrumental role in addressing the limitations of existing methods 
by providing a means to reproduce and pharmacologically modulate key aetiologies and 
clinically relevant integrated downstream responses at varying levels of complexity.
The potential of organ-on-chip approaches for testing drug efficacy has been explored in a 
recent study that developed a microengineered 3D assay of epithelial– mesenchymal 
transition (EMT) during cancer progression37 (FIG. 2c). By culturing lung cancer spheroids 
in a 3D matrix gel adjacent to an endothelialized microchannel, this model recapitulated 
EMT-induced tumour dispersion and phenotypic changes in cancer cells in an endothelial 
cell-dependent manner. To demonstrate the potential of this system as a drug screening 
platform, 12 drugs — ranging from prospective drugs early in the discovery pipeline to US 
Food and Drug Administration (FDA)-approved drugs — were introduced to the vascular 
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channel, and their ability to inhibit EMT was analysed by direct visualization of the cancer 
spheroids. Interestingly, the effective drug concentrations in this model differed by as much 
as three orders of magnitude from those measured in a conventional 2D dispersion assay. 
Moreover, the relative rankings of the 12 drugs, as ordered by the concentration required to 
inhibit EMT, were not consistent with results from 2D culture. More importantly, the 
efficacious concentrations determined by this cancer-on-a-chip system were closer 
approximations of effective drug concentrations in humans measured during clinical trials 
than were the concentrations determined from the 2D model. This type of efficacy 
comparison between lead compounds and currently marketed drugs could have a profound 
influence on go/no-go decisions during lead optimization, as it is desirable for candidate new 
molecular entities to outperform other available options in some capacity. Similar 
discrepancies between effective drug concentrations predicted by organ-on-chip systems and 
those by traditional 2D assays have been demonstrated using a microengineered model of a 
mammary duct in breast cancer38 and a multi-organ model of uterine cancer, the liver and 
bone marrow39.
An in vivo tissue engineering strategy was recently used to increase the complexity and 
physiological relevance of organs-on-chips40. This study described a novel method in which 
a polymeric chamber containing bone-inducing materials was implanted into murine hosts to 
generate new bone that encased intact living bone marrow, which was then removed from 
the chamber and cultured in a microfluidic device40 (FIG. 3). This bone-marrow-on-a-chip 
system reconstituted a complex 3D haematopoietic niche and preserved bone marrow-
specific organ functionalities by maintaining the spatial distribution and physiological 
proportions of haematopoietic stem cells and progenitor cells in vitro. In this system, 
granulocyte colony-stimulating factor promoted bone marrow recovery after exposure to 
clinically relevant doses of γ-radiation, a therapeutic implication that was not evident in 
conventional bone marrow culture systems. By using the in vivo environment to 
precondition engineered tissue, this system retained complex physiological activities while 
leveraging microfluidics for sample manipulation and assessment.
Similarly, another study cultured ex vivo brain tissue retaining complex in vivo neural 
network connections and electrophysiological behaviour in a microsystem that permitted 
localized pharmacological treatment41 (FIG. 4). Specifically, two thin brain tissue slices 
were enclosed in neighbouring microfluidic channels and allowed to form synaptic 
connections, resulting in synchronized electrophysiological burst activity. The culture 
medium in one microchannel was supplemented with kynurenic acid, a glutamate receptor 
antagonist, which selectively inhibited the spontaneous electrical excitation of the treated 
brain slice with no effect on the other slice. This study demonstrates the potential for 
integrating ex vivo tissue with organ-on-chip platforms to probe higher-order functionality 
of complex tissue with precise spatiotemporal chemical and pharmacological intervention 
for drug efficacy studies.
As illustrated by these studies, engineering organ-on-chip microdevices using in vivo 
environments or ex vivo tissues may be a viable strategy for model development and 
optimization, especially when conventional in vitro approaches are not fully capable of 
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replicating the organ-specific structural and functional complexity that is critical for reliable 
assessment of drug efficacy.
Toxicity screening
Unexpected adverse drug effects are the second most common cause of clinical trial failures 
and are also responsible for the costly withdrawals of marketed drugs. Established 
biochemical models can evaluate specific and anticipated mechanisms of toxicity (for 
example, hERG (also known as KCNH2) channel binding; the hERG is a potassium voltage-
gated channel), and cellular models can monitor simplistic end points such as cytotoxicity. 
Animal testing often fails to detect important human toxicities and can cause unnecessary 
rejection of drug candidates based on animal-specific pathways of toxicity. Organ-on-chip 
technology could be used to assess human-relevant drug responses for anticipated toxicities 
at various levels of biological complexity (that is, the subcellular, cellular, tissue and organ 
levels) and to detect unanticipated off-target toxicities.
The primary focus of research in this area has been on microengineered liver models, owing 
to the current emphasis on testing for hepatotoxicity and the central role of hepatic drug 
metabolism in adverse drug reactions. The proof of principle for this approach has been 
demonstrated in recent studies that utilized human liver-on-a-chip devices for metabolomic 
analysis of hepatotoxicity. For example, microfluidic culture of human hepatocytes was 
coupled with NMR spectroscopy to develop a bioanalytical platform for monitoring 
metabolic responses of hepatocytes to the anticancer drug flutamide and its active metabolite 
hydroxyflutamide, both of which are known to possess hepatotoxic properties42. Through 
quantitative analysis and mapping of metabolic and mitochondrial activities, the 
investigators identified metabolic signatures of toxic drug responses in this model, and 
delineated metabolic pathways involved in the induction of hepatotoxicity due to flutamide 
and hydroxyflutamide. The organ-on-chip approach leveraged in this study was instrumental 
in reducing biological noise inherent to in vivo metabolomics models, and revealed a 
potential source of hepatotoxicity-specific biomarkers.
A similar strategy was used in creating a microengineered model that integrated microfluidic 
culture of human hepatocytes embedded in a 3D hydrogel with in-line mass spectrometry to 
study the toxicity of acetaminophen metabolites43. Furthermore, extension of this approach 
made it possible to model the secondary toxic effects of drug metabolites produced in the 
liver on other organs, as demonstrated by a microfluidic liver–kidney model that simulated 
the systemic interaction between these two organs and demonstrated nephrotoxic responses 
to the hepatic metabolite of ifosfamide44. More recently, researchers have begun to explore 
the potential of organ-on-chip technology beyond hepatotoxicity screening by developing 
microdevices that enable the reconstitution and monitoring of contractile functions of heart 
muscle for quantitative analysis of drug-induced cardiotoxicity45–49.
Organ-on-chip microsystems can also be used to model clinically relevant off-target drug 
toxicities other than liver and heart failure. For example, we recently used a microengineered 
lung-on-a-chip model to simulate the pulmonary oedema caused by the dose-limiting 
toxicity of IL-2 that is observed in patients with cancer15. When the vascular microchannel 
lined with human microvascular endothelial cells was treated with clinically used 
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concentrations of IL-2, this microdevice replicated the leakage of intravascular fluid into the 
air-filled alveolar compartment and concomitant flooding of the air space. Intra-alveolar 
deposition of fibrin clots caused by the activation of coagulation cascades was also observed 
in this model, which is another clinically relevant toxic response that occurs during the 
course of IL-2-induced pulmonary oedema. High-resolution microfluorimetric analysis of 
the alveolar–capillary interface showed that the IL-2 toxicity-induced oedematous responses 
are elicited by compromised intercellular junctions and resultant increases in barrier 
permeability. Furthermore, this mechanically active model was capable of mimicking 
physiological breathing motions, and breathing-generated mechanical forces were found to 
increase IL-2-induced tissue injury50. This injury was effectively inhibited by potential drug 
candidates, such as angiopoietin-1 and a newly developed transient receptor potential 
vanilloid 4 (TRPV4) ion channel blocker50.
Organ-on-a-chip models can therefore be used for accurate prediction and mechanistic 
investigation of dose-limiting human toxicities of prospective drugs, as well as for the 
exploration of new therapeutic approaches to mitigate the observed toxic effects. In the drug 
discovery pipeline, predictions made by these models could inform and facilitate early 
efforts to identify, modify and optimize lead compounds, thus developing safer drugs with 
increased likelihood of success in clinical trials51.
Pharmacokinetics and body-on-chip systems
Several studies have demonstrated the potential of organ-on-chip microdevices to model key 
pharmacokinetic processes that govern drug bioavailability, with a strong emphasis on drug 
metabolism. Liver-on-a-chip models integrated with physiologically based pharmacokinetic 
computational models have been particularly useful for predicting rates of metabolic drug 
clearance that correlate with clinical data52. For instance, this integrative liver-on-a-chip 
approach was used to culture human primary hepatocytes in 12 parallel microfluidic 
chambers and to test the metabolism of 7 drugs simultaneously53. Detection and 
quantification of drug metabolites revealed that five cytochrome P450 enzymes — mediators 
of phase I drug metabolism — were active in these systems. Moreover, drug clearances in 
this microsystem predicted by a physiologically based pharmacokinetic model closely 
matched those in previously reported clinical studies. Similar predictive capabilities were 
demonstrated in another study that used microfluidic perfusion culture of primary human 
hepatocytes to investigate the clearance of six marketed drugs54.
Advances in organ-on-chip technology have also made it possible to develop in vitro models 
of other critical processes that determine the bioavailability of drug compounds, such as 
absorption and excretion. For example, Kim and colleagues55,56 created a 3D microfluidic 
system consisting of two overlapping cell culture chambers separated by a transparent 
elastomeric membrane lined with Caco-2 cells to model the intestinal barrier. This gut-on-a-
chip system enabled prolonged culture of microbial cells on the epithelial surface in the 
presence of physiological luminal flow and used negative pressure-driven membrane 
stretching to mimic peristaltic motions to recapitulate the dynamic mechanical 
microenvironment of the intestine. Three-dimensional tissue microstructures that resembled 
intestinal villi and consisted of heterogeneous cell populations of native intestinal epithelium 
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formed in this environment. Importantly, this model reproduced characteristic absorptive 
properties and the barrier function of the human intestine, which may be particularly useful 
for drug absorption studies55,56. In addition, this system allowed for co-culture with 
intestinal bacteria, and so could be used to investigate the role of the gut microbiome in drug 
absorption. The compartmentalized channel design of this system was also used in a 
separate study to generate a model of the intestine–capillary interface57. By integrating 
microfluidic cell culture of Caco-2 cells on a semi-porous membrane with in-line mass 
spectroscopy, this model enabled real-time analysis of intestinal permeability to a model 
drug, curcumin, and generated data consistent with previous findings on human intestinal 
barrier function.
Although these individual organ models offer compelling advantages, there has been 
increasing recognition that the full potential of organ-on-chip technology for preclinical 
testing, particularly for modelling pharmacokinetics and pharmacodynamics, can only be 
realized by integrating these models to recapitulate human physiology at the whole-body 
level. Motivated by this vision, researchers have begun to pursue the development of multi-
organ models capable of replicating sequential processes that influence drug activity within 
the body. The most common approach to creating this type of system is to link together 
multiple microengineered organ models via a fluidic network that allows for their functional 
integration and interaction in a physiologically relevant manner. Recent advances in the field 
have been made possible by the unique capability of these human ‘body-on-a-chip’ systems 
to predict body-level drug responses that reflect both complex organ-level effects and organ–
organ interactions58,59. One such study combined models of breast cancer, the intestine and 
liver to establish a network of interconnected microfabricated cell culture chambers to 
demonstrate the sequential absorption, metabolism, and efficacy of four anticancer drugs60 
(FIG. 5a). An extension of this system incorporated a gastric acid stomach chamber to 
simulate gastrointestinal digestion of drugs before intestinal absorption, demonstrating that 
integrated human models can be developed to capture entire physiological processes that 
determine bioavailability and efficacy of orally administered drugs61.
Body-on-chip strategies have also been useful in modelling the circulation and excretion of 
drugs. For example, an integrated model consisting of a microengineered peristaltic pump 
and an albumin-containing blood simulant to mimic circulating blood, a dialysis membrane 
to simulate excretion, and a chamber containing breast cancer cells was used to evaluate 
anticancer drug excretion and retention62. In this model, the retention and efficacy of thio-
TEPA (N,N′N′-triethylenethiophosphoramide) and docetaxel was greatly influenced by their 
affinity for albumin.
The design and operation of these microengineered multi-organ models are often 
challenging and require careful consideration of allometric scaling principles63. As an 
organism is scaled down to a microdevice model, imbalances are inevitable between 
parameters that scale differently with size. Within a single organ microsystem, these include 
media volume, cell number, drug concentration and reaction kinetics. When multiple organ 
models are linked together, additional parameters such as relative organ volumes, blood flow 
rates, organ interaction times and drug–tissue partition coefficients become important. To 
predict drug performance in these models, we must anticipate scaling effects, identify 
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critical parameters depending on the purpose of the particular model (for example, 
mechanistic proof-of-principle or dose determination), and design the system to ensure that 
the parameters accurately reflect in vivo values.
To address these scaling considerations, Shuler and colleagues64 pioneered the application 
of pharmacokinetic and pharmacodynamic modelling principles to develop more 
physiologically realistic integrated systems known as micro cell culture analogues. For 
example, a multi-organ model comprising interconnected microchambers representing a 
colon tumour, the liver and bone marrow recapitulated the in vivo distribution, retention and 
recirculation of drug-containing blood in these organs (FIG. 5b). In this model, the residence 
times of medium in each organ compartment were matched to blood residence times in the 
in vivo counterparts. Moreover, integration of 3D cell culture in hydrogels in this system 
enabled the investigation of hepatic metabolism-mediated cytotoxicity of the prodrug tegafur 
to colon cancer, liver cancer and bone marrow cells.
In another study, the same group demonstrated the applicability of these systems to link in 
vitro micro cell culture analogues with computational pharmacokinetic and 
pharmacodynamic models65. A microfluidic device was created to model tegafur and 5-
fluorouracil anticancer activity by recirculating common media through colon cancer, liver 
and bone marrow compartments. Toxicity data from this study were analysed in conjunction 
with a computational, physiologically based pharmacokinetic and pharmacodynamic model 
that reflected flow rates, media volumes, drug concentrations, reaction kinetics and cytotoxic 
activity in the microdevice. In this analysis, experimentally measured cytotoxicity was used 
to refine the computational model to generate more accurate estimates of hepatocyte, colon 
carcinoma and haematopoetic stem cell death in vivo. This study demonstrates an integrative 
strategy that combines microengineered cell culture with a numerical pharmacokinetic and 
pharmacodynamic approach to address scaling allometry in organ-on-chip models and to 
produce human-relevant pharmacokinetic and pharmacodynamic predictions.
These studies suggest that organ-on-chip technology could be used to develop novel assays 
to simulate and predict critical physiological responses involved in drug bioavailability, 
efficacy and toxicity.
Phenotypic screening
Target-based drug discovery requires the generation and testing of specific mechanistic 
molecular hypotheses to identify therapeutic targets and drug candidates, whereas the newly 
resurgent process of phenotypic drug discovery is driven by screening of specific 
physiological responses in cell-based or animal models66. The goal of phenotypic screening 
is to identify active compounds that ameliorate disease phenotypes without initial concern 
for the molecular mechanisms of action of the identified compounds.
For effective phenotypic screening, it is critical that the assay captures various aspects of 
complex human physiology while remaining amenable to high-throughput manipulation for 
efficient appraisal of large compound libraries. However, despite recent efforts towards assay 
development and automation, current phenotypic models leave substantial room for 
improvement to meet both of these requirements. Animal assays have been productive and 
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serve as a more physiological approach but remain expensive, whereas cell-based assays do 
not generally provide valuable phenotypic data except in particular cases in which static 
multi-well plate cell culture can express complex behaviour (for example, angiogenesis67). 
These limitations can be addressed by the intrinsic advantages of organs-on-chips, which 
offer small-scale platforms with low reagent-volume requirements that are compatible with 
automated imaging-based analytics.
For example, Trietsch et al.68 developed a microengineered high-throughput 3D cell culture 
platform that modified a conventional 384-well plate to create as many as 96 independent 
organ-on-chip microchambers. Each chamber contained three interconnected parallel 
microchannels that enabled the formation and continuous perfusion of cell-laden hydrogels. 
This microdevice was used to co-culture human hepatocytes with fibroblasts to assess a 
concentration-dependent hepatotoxic response to rifampicin. Hepatocyte viability decreased 
when rifampicin concentrations exceeded 160 μM, and this toxic response became more 
pronounced with longer exposure times. Similar platforms, with self-assembled 3D tissues 
in microengineered matrices, were used to create an array of contractile cardiac microtissues 
that permitted simulation of arrhythmia and higher-throughput screening of phenotypic 
changes48. The cardiac microtissues in this model exhibited a high-frequency activation rate 
with no rest period, similar to an in vivo reentrant state of arrhythmia. Moreover, an 
electrical defibrillation stimulus could revert this phenotype to a normal rhythm. These types 
of organ-on-chip models are constructed in conventional multi-well plates and are therefore 
readily scalable and fully compatible with standard liquid handling and analytical 
equipment, which is important for higher-throughput phenotypic screening.
Phenotypic screening can also be used to investigate approved drugs or drugs that failed to 
meet their primary efficacy end points in Phase III clinical trials, and repurpose them for the 
treatment of other diseases. The majority of successfully repositioned drugs have been 
identified through serendipitous findings in animal studies, clinical trials and clinical 
practice, all of which are expensive. It has therefore been suggested that phenotypic 
screening using predictive preclinical models may be the most efficient and cost-effective 
way to reposition drugs1,69,70. Researchers have already begun to explore the application of 
organs-on-chips as predictive phenotypic assay platforms for drug repositioning. For 
example, a microengineered model of liver cancer was used to investigate the anticancer 
effects of artemisinin, an antimalarial drug that is currently being considered for use as a 
cancer therapy71. In this model, human liver cancer cells self-assembled into 3D tumour 
structures and their invasive migration into neighbouring micropatterned 3D gel matrices 
was examined under physiological interstitial flow. Microfluidic delivery of artemisinin to 
the solid tumours led to increased cell–cell adhesion and effective inhibition of cancer cell 
migration, thus demonstrating the potential of the drug as an anticancer therapeutic. When 
combined with the continuing progress in creating microengineered multi-organ models of 
integrated whole body physiology, this organ-on-chip-based phenotypic screening approach 
might greatly facilitate the increasing efforts to harness the potential of drug repositioning.
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In addition to improving research and development efficiency in general, organ-on-chip 
platforms could be useful to support and accelerate efforts in rare diseases, stratified 
medicine and nanomedicine, fields that are attracting increasing industrial interest. 
Exploring these further applications could be facilitated by the integration of organs-on-
chips with other emerging disease modelling techniques, such as sourcing cells from patients 
to develop induced pluripotent stem cells (iPS cells), or modifying normal stem cells with 
new gene editing tools (for example, the clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas system).
Rare diseases
Rare diseases have attracted growing commercial interest in recent years72. However, the 
development of new drugs for these diseases is greatly hampered by the lack of appropriate 
preclinical models and the scarcity of patient populations available for clinical trials; 
therefore, organ-on-chip technology could have a role in developing better models. For 
example, a heart-on-a-chip model incorporating genetically engineered iPS cells revealed 
that contractile weakness of cardiomyocytes in Barth syndrome is caused by a mutation in 
the gene encoding tafazzin, thus providing insight into key disease mechanisms that may 
reveal potential therapeutic targets for this rare disease36. In a similar attempt to model 
hereditary haemorrhagic telangiectasia, van der Meer and colleagues73 utilized a 
microfluidic device to engineer 3D vascular tissue constructs into blood vessel-like tubular 
structures. Interestingly, inhibition of transforming growth factor-β signalling pathways in 
this model resulted in the formation of disorganized and tortuous vascular tubes that closely 
resembled the abnormal blood vessels characteristic of the disease. This model may provide 
a basis for further investigation of the biological underpinnings of haemorrhagic 
telangiectasia.
Stratified medicine
The practice of developing drugs for particular patient populations — for example, stratified 
on the basis of the presence of a particular biomarker linked to disease or drug response — 
has become increasingly prevalent in recent years. One path to population-specific drugs is 
through post-hoc analysis of large clinical trials, but this approach is burdened by the need 
for enlarged and therefore more expensive clinical trials to allow analysis of statistically 
significant differences even between small subgroups74. As highlighted in the “Enrichment 
Strategies for Clinical Trials” recently published by the FDA75, this problem is being tackled 
by the prospective use of specific patient characteristics to select subpopulations that are 
more likely to show desired drug responses. Clearly, preclinical models that enable these 
types of predictive studies earlier in the pipeline could help refine patient pools for clinical 
trials.
To this end, organ-on-chip technology has been applied to develop in vitro models that 
reflect genetic underpinnings of variability in human drug responses. For example, a two-
organ model was constructed in a microdevice consisting of two interconnected 
microchambers that supported 3D culture of brain tumour and liver cells76. By incorporating 
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liver cells expressing varying levels of cytochrome P450 subtypes, a set of metabolic 
enzymes with significant ethnic variation77, this study examined differential responses of 
tumour cells to the anticancer drug ifosfamide. Activation of ifosfamide by the liver cells 
and resultant cytotoxic effects on the tumour cells were found to depend heavily on the level 
of CYP3A4 expression in liver cells. The combination of organs-on-chips and iPS cells may 
further provide a relatively inexpensive method to generate patient- and population-specific 
model platforms that could be used to test drugs that target specific mutations or 
polymorphisms.
Another recent development in this area is to perform complementary animal studies in 
parallel with human trials78. These co-clinical trials are designed to reflect the relevant 
genetic diversity of the human patient population by using cells derived from the patients in 
the trial to generate xenograft models, with the goals of predicting patient responses and 
studying the factors that contribute to outcome variability. For instance, co-clinical studies 
could identify genetic biomarkers that are predictive of therapeutic outcomes, and these 
biomarkers could be immediately validated in patients. Organs-on-chips could provide 
genetically matched platforms for early prediction and mechanistic investigation of patient 
response or resistance to therapy, biomarker identification and screening of panels of 
possible therapy adjustments in the event of drug resistance or relapse. For future 
personalized medicine and co-clinical trial applications, a patient’s own cells could be 
adapted with iPS cell techniques to develop patient- and population-specific organs-on-chips 
for truly individualized study of drug safety and efficacy or drug–drug interactions.
Nanomedicine
Recent growth in nanotechnology has fuelled intense efforts to apply research in this area to 
the development of therapeutics. Examples of promising approaches include the use of 
nanoparticles for delivery and localization of drugs to specific tissues of interest and for 
packaging of pharmaceuticals that would otherwise have limited bioavailability79,80. 
However, the novelty of this approach raises concerns regarding the potential adverse effects 
of the nanomaterials involved. So, the development, optimization and clinical translation of 
nanomedicines require rigorous preclinical assessment of drug-induced toxicity as well as 
efficacy, but these studies are challenging because of the lack of test platforms that 
incorporate sufficient human-relevant physiological complexity for reliable prediction of 
drug effects.
To provide proof of principle for using organ-on-chip approaches to meet the needs for 
inexpensive, predictive models in nanomedicine, Kim et al.81 used a blood vessel-on-a-chip 
to study the translocation of lipid–polymer hybrid nanoparticles across a microfluidic 
endothelium mimicking the dysfunctional endothelial barrier of atherosclerosis. Importantly, 
key findings from this microengineered in vitro model were corroborated by data from 
animal studies using a rabbit model of atherosclerosis81. Similar approaches could make it 
possible to model and study transport of nanotherapeutics across other critical barriers in the 
body such as the gut55,56 and the blood–brain barrier82–85. Furthermore, extension of this 
strategy based on integrated multi-organ models could be instrumental in evaluating 
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functional sustainability and bioavailability of nanotherapeutic agents such as 
nanoengineered RNA interference therapies86.
Current challenges and limitations
Realizing the full potential of organ-on-chip technology comes with technical and 
entrepreneurial challenges. One of the critical technical challenges arises from materials 
such as poly(dimethylsiloxane) (PDMS) that have gained widespread use in rapid-
prototyping of organ-on-chip microdevices. Existing organ-on-chip models rely heavily on 
cell culture substrates made of synthetic materials (for example, PDMS, polycarbonate and 
polyester), the physicochemical properties of which are not appropriate for mimicking 
extracellular matrices in vivo, and new cell culture substrates are needed87. For example, 
PDMS has been shown to absorb small hydrophobic molecules20,88, which may lead to 
reduced effective drug concentrations and pharmacological activities. Researchers have 
already begun to address this problem by using chemical surface modification89 or 
alternative materials90,91. Challenges associated with standardizing and automating the 
highly variable current PDMS fabrication techniques originally developed for laboratory 
prototyping also pose major technical hurdles to large-scale manufacturing and higher-
throughput operation of organ chips, which are important steps for industrial adoption of this 
technology. Successful translation of organs-on-chips from proof of concept in the 
laboratory to commercial screening platforms will require the identification and optimization 
of new low-cost materials and fabrication strategies suitable for their mass production and 
integration into existing infrastructures in the pharmaceutical industry.
More reliable and sustainable sources of human cells, especially disease-specific cells, that 
are amenable to in vitro culture in organs-on-chips and phenotypically represent their in vivo 
counterparts are also needed. Although questions remain regarding the phenotypic maturity 
of their differentiated progeny, human embryonic stem cells and iPS cells have the potential 
to serve as cell sources that can be engineered to suit specific needs in the development of 
organs-on-chips92,93. This approach is particularly attractive given the capability of organ-
on-chip models to generate and control physiologically relevant structural, biochemical and 
mechanical cues that instruct stem cell differentiation and maturation.
For the analysis of biological responses, the low culture volumes and cell numbers in 
organs-on-chips often give rise to technical issues associated with detection sensitivity. This 
challenge may be met by leveraging advances in lab-on-a-chip technologies94 to integrate 
organ-on-chip models with bioanalytical platforms microengineered with miniaturized 
optics and sensors that enable high-resolution biochemical analysis with substantially 
reduced sample volume requirements. In addition, for effective model validation, the 
readouts of organs-on-chips must map to the standard clinical end points they are designed 
to model. This type of correlation will better enable translation and interpretation of results 
from organs-on-chips. However, mapping organ-on-chip readouts to their clinical 
counterparts is currently difficult owing to major differences in measurement techniques49. 
Computational modelling will be necessary to correlate the more simplified readouts of 
organs-on-chips to their corresponding clinical diagnostics and to provide context for 
translation to a patient response.
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Another overarching consideration in organ-on-a-chip development is the balance between 
complexity and practicality. Increasing the complexity of an organ-on-a-chip model is 
required for improving its physiological relevance; however, this often presents major 
challenges to practical operation and management of the system. Given the capability of 
organs-on-chips for precise control of cell culture parameters, this balance may be achieved 
by identifying the minimal subset of cells and microenvironmental factors necessary to 
create the simplest model possible that recapitulates physiological responses of interest. If 
complexity is inevitable, however, the practicality of organs-on-chips can be improved by 
developing automated instrumentation that enables the following capabilities: physiological 
integration, maintenance and monitoring of microengineered cell culture models; control of 
cellular exposure to drug compounds with high spatiotemporal precision; and sample 
collection and real-time analysis of drug responses. These capabilities will be particularly 
useful to examine chronic disease progression and long-term drug effects95,96, which require 
long-term culture and are currently a major challenge. Animal models are currently better 
suited to address these questions.
Improved automated instrumentation will also facilitate the development of body-on-chip 
models by providing independent, simultaneous control of different cell types within a 
single device. The success of these integrated models, however, will still rest on the 
development of a common culture media that can support various types of cells and mediate 
their biochemical communication. Formulation of such media will require a fundamental 
understanding and careful consideration of cell type-dependent responses to various soluble 
cues such as serum, growth factors and hormones. Alternatively, microengineered systems 
could be developed that utilize conventional multi-well plates for parallel microfluidic cell 
culture and replace external flow pumps with standardized robotic liquid handling 
systems68,97.
Organs-on-chips are not universal solutions, and alternative tools will continue to be better 
solutions for modelling certain in vivo processes. In vitro models recreating the complex 
biology of the endocrine, immune and nervous systems remain beyond the capabilities of 
organs-on-chips. Use of ex vivo tissue as described in the ‘Efficacy’ section above could 
eventually be used to study these systems, but predicting clinically relevant drug effects will 
continue to require the use of animal models for some time. Multi-organ-on-chip systems 
have been used for toxicity testing; however, these studies have not been used for broad, 
systematic off-target toxicity, which remains a task more appropriate for animal testing or 
adverse outcome pathways analysis. Also, although several organs-on-chips have been used 
for pharmacological dose-finding studies (as discussed in the ‘Pharmacokinetics and body-
on-chip systems’ section), computational pharmacokinetic modelling based on 
physicochemical drug properties and estimations of metabolism is a lower-cost alternative 
for early preclinical estimates of bioavailability, and animal testing continues to be a more 
complete predictive tool for later testing.
In the many cases in which organs-on-chips offer improved biological modelling, alternative 
methods may still be preferable for practical considerations. In target identification and 
validation, efficacy testing and toxicity testing, it is not always critical to recapitulate 
integrated, organ-level functionality, and in these cases more cost-effective biochemical and 
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cellular assays can be effectively implemented. It is also important to recognize that organ-
on-chip model development will take a substantial amount of time to become suitable for 
standard use throughout the drug discovery process, whereas existing biochemical, cellular 
and animal models offer off-the-shelf solutions validated for regulatory acceptance.
Although many of the above challenges may be addressed by progress in the organ-on-a-
chip field, there are also intrinsic limitations that organs-on-chips may never circumvent. 
These model platforms necessarily include only a subset of the entire milieu of cell types, 
tissues, organs and systems present in vivo, and therefore will not detect every possible off-
target toxicity. Animal tests instead offer whole-organism toxicity testing, so there may be 
persistent value for supplementing organs-on-chips with whole-animal studies. For 
reductionist investigations throughout the drug discovery and development process (for 
example, water solubility for bioavailability and interrogation of mechanism-of-action of 
identified toxicities), organs-on-chips may include irrelevant complexity, resulting in 
unnecessary costs and measurement variability compared to biochemical and cellular assays 
or in silico analyses. Similarly, organ-on-chip testing will be more costly than biochemical 
and cellular testing in high-throughput contexts. For screening a large compound library for 
target activity, it is unlikely that organs-on-chips will improve accuracy enough to justify 
their added costs over traditional high-throughput biochemical and cellular assays.
Opportunities to be explored
From a technological standpoint, extending the current state-of-the-art in organ-on-chip 
technology will provide new opportunities to model several organs that have not yet been 
fully explored in this field. Of particular interest are those in the nervous, endocrine, sensory, 
digestive and reproductive systems that are often a target of therapeutic intervention and/or 
affect the pharmacological activity of drugs. Success in this endeavour will require the 
formation of alliances between engineers, biologists, computational biologists and clinicians 
to devise new methodologies for capturing the essential components of the physiology of 
target organs.
Organ-on-chip technology can be synergistically integrated with modelling and analysis 
tools already used in drug discovery. Many validation technologies are designed 
predominantly for molecular-level analysis of therapeutic targets, but can be complemented 
by organs-on-chips to predict organ-level responses. For example, organ-on-chip models 
could be used to validate potential targets identified by genomics and proteomics analyses. 
A similar synergy can be achieved in the later steps of the drug discovery process. For 
instance, organs-on-chips may serve as a complementary tool in adverse outcomes pathway 
analysis98 to detect novel toxicities that are not covered by established libraries of known 
toxic interactions. For the development of specialized therapeutics such as medical 
countermeasures against radiological, chemical or biological agents for which it is unethical 
to conduct human clinical trials, organs-on-chips may augment animal studies conducted 
under the FDA’s Animal Rule99.
Organs-on-chips could also be used to model drug delivery and transport through complex 
3D tissues (for example, solid tumours). This is an important consideration for 
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pharmacodynamic analyses to determine or validate drug doses and administration regimens 
required to achieve desired therapeutic effects. In addition, sampling and analysis of 
conditioned medium from these physiological 3D models could be used to identify or 
validate predictive biomarkers of drug efficacy and toxicity.
Another important area of opportunity for future studies is the application of organ-on-chip 
technology for the development of predictive human disease models. For example, one area 
of potential interest is to use organs-on-chips to model paediatric diseases and rare diseases, 
studies of which are limited due to the paucity of in vitro modelling approaches, small 
patient populations and limited patient availability. Reliable cell sources will be important 
for organs-on-chips to contribute to the development of predictive human paediatric disease 
models.
Perhaps even more critical for the progression and maturation of this field is to develop 
robust strategies to recapitulate the functional integration of multiple organs and to simulate 
human physiology and pathology at the whole-body level. The most promising prospective 
application of body-on-a-chip (as well as organ-specific) systems is to bridge the large gap 
between preclinical predictions based on animal studies and the actual outcomes of clinical 
trials100. In the near term, organ-on-chip technology may serve as a complementary 
preclinical approach that could support or disprove predictions from animal testing before 
clinical studies.
Outlook
Despite their limitations, organs-on-chips have the potential to play a transformative role 
across drug discovery and development. Rigorous validation of this technology using not 
only animal data but, more importantly, the results of clinical trials is required to determine 
whether organ-on-chip models accurately represent human-relevant physiology and show 
predictive capability across broad drug classes and clinical outcomes.
Eventually, organ-on-a-chip models may play a pivotal role in streamlining the clinical trial 
process. For example, advances in stem cell engineering could be integrated into organ-on-
chip technology to develop personalized models to predict patient-specific toxicity and 
efficacy, which could lead to more efficient human trials with significantly reduced 
preclinical testing requirements. These personalized models may also be useful in exploring 
patient-specific biomarkers and individualized dosing regimens based on patient-specific 
pharmacokinetics101. In a related strategy, organ-on-chip models could be used to explore 
broad population genetic variations that could reduce the required size of clinical trials.
Ultimately, the organ-on-a-chip field will only achieve its full potential with translation into 
commercial drug discovery. This undertaking requires that organ-on-a-chip models become 
packaged test solutions acceptable to the pharmaceutical industry: assays must be reliable 
and robust, and not require specialized personnel with unique technical expertise. Regulatory 
agencies are understandably circumspect in accepting new sources of data as justification for 
human trials, therefore organ-on-chip models will also have to survive stringent validation to 
serve as formal preclinical tests. Achieving the necessary levels of development and 
validation for commercial marketability is, at its heart, an entrepreneurial challenge. Such 
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challenges include the requirement of start-up funding for technical development, industry 
and regulatory acceptance, and historical validation of data, all of which constitute a 
multidimensional chicken-or-egg dilemma, as each necessary component is difficult to 
achieve without prior attainment of the other components. However, these hurdles could be 
surmountable with tri-lateral partnerships between academic institutions, industry and 
regulatory agencies. As illustrated by the recent launch of US federal funding programmes 
for integrated microphysiological systems102,103, government and regulatory agencies have 
recognized the paradigm-shifting potential of organ-on-chip technology. Pharmaceutical 
companies are also beginning to establish partnerships with leading academic institutions to 
jointly explore this technology and to position themselves at the forefront of expected organ-
on-a-chip advances.
Achievements in the organ-on-a-chip field could present exciting new avenues for drug 
discovery and development. Much remains to be done, and accordingly there is a wealth of 
opportunities to participate in what we hope will be a surge of innovation to realize the 
tremendous potential that organ-on-chip technology holds.
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Glossary
Biomimetic Refers to the use of principles, mechanisms and designs derived from 




(EMT). The process by which a polarized epithelial cell undergoes a 
series of biochemical changes to acquire characteristics of a 
mesenchymal cell, including increased invasive and migratory 
capacity, higher resistance to apoptosis and upregulated production of 
extracellular matrix proteins
Microfluidics A science and engineering discipline focusing on the development of 
fluidic systems with characteristic dimensions of tens to hundreds of 
micrometres that provide capabilities to control, manipulate and 
analyse small volumes of fluids (microlitres to attolitres) for a wide 
range of applications
Spheroids Three-dimensional spherical agglomerations of adherent cells 
generated by intercellular adhesion and aggregation
Stratified 
medicine
An approach that aims to develop patient-specific therapies using 
biological or risk characteristics (for example, biomarkers and 
genetics) shared by subgroups of patient populations. This approach is 
also referred to as personalized or precision medicine
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a | A human breathing lung-on-a-chip was created by co-culturing human alveolar epithelial 
cells and pulmonary microvascular endothelial cells on opposite sides of a stretchable 
porous membrane to replicate the alveolar–capillary boundary of the breathing human lung. 
A vacuum was applied to mimic the tissue stretch that occurs during normal breathing. b | 
This system was used to reconstitute integrated organ-level functions such as inflammatory 
responses to intra-alveolar pathogenic bacteria such as Escherichia coli that are mediated by 
endothelial recruitment of circulating neutrophils, transmigration through the alveolar–
capillary interface and subsequent bacterial phagocytosis. c | The lung-on-a-chip was used to 
model human lung diseases such as pulmonary oedema. Administration of interleukin-2 into 
the microvascular channel resulted in fluid leakage into the alveolar compartment, 
recapitulating the pulmonary oedema induced by acute toxicity of interleukin-2 that is 
observed in patients with cancer.
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Figure 2. Organ-on-a-chip models for cancer research
a | A microvascular endothelium-on-a-chip created in a compartmentalized microfluidic 
device enabled basal stimulation and activation of endothelial cells grown on a porous 
membrane using chemokines to study the attachment of circulating breast tumour cells 
involved in cancer metastasis. The effect of chemokines, such as tumour necrosis factor, was 
investigated by adding these agents to the bottom channel. More cancer cells attached to the 
endothelium that was pre-treated with tumour necrosis factor than to untreated endothelium. 
b | The metastasis of breast cancer cells to bone was studied using human umbilical vein 
endothelial cells grown in a microfluidic channel adjacent to a 3D collagen gel containing 
bone cells differentiated from human bone marrow-derived mesenchymal stem cells 
(MSCs). Migration of the cancer cells into the bone was observed. c | To study epithelial–
mesenchymal transition in cancer, lung cancer spheroids were embedded in micropatterned 
3D matrices immediately contiguous to a microchannel lined with endothelial cells. 
Analysis of epithelial–mesenchymal transition is conducted using microfluorometry to 
detect dispersion of the cancer spheroids. PDMS, poly(dimethylsiloxane).
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Figure 3. In vivo engineering of bone marrow
A bone marrow-on-a-chip model leveraged in vivo tissue engineering approaches to generate 
fully functional engineered bone marrow (eBM) for incorporation and perfusion culture in a 
microfluidic device. The eBM had a physiological structure and was used in an organ-on-a-
chip system to study depletion and pharmacological protection of haematopoietic stem and 
progenitor cell populations exposed to γ-radiation. The red and green channels are medium 
perfusion channels used to maintain the eBM in the central chamber. PDMS, 
poly(dimethylsiloxane).
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Figure 4. Brain tissue-on-a-chip
Higher-order functionality of the nervous system can be studied in a microdevice that 
enables culture of two brain tissue slices in separate media formulations. The two tissue 
slices are allowed to communicate by synaptic connections formed through microchannels 
between the culture chambers. Electrodes incorporated into this system enable measurement 
of synchronous electrophysiological activity between the two brain slices. This design 
allows for selective pharmacological treatment of only one tissue slice and measurement of 
its effects across the synaptic connections.
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Figure 5. Body-on-chip systems
A | A microdevice containing interconnected cell culture microchambers was used to 
develop a multi-organ model that integrated microfluidic culture of intestinal epithelial cells, 
hepatocytes and breast cancer cells to simulate absorption, metabolism and activity of 
anticancer drugs. b | A micro cell culture analogue (μCCA) was created by linking together 
three interconnected microfluidic cell chambers representing a colon tumour, the bone 
marrow and liver with proportional physiological scaling to develop a more realistic 
physiological model of drug metabolism and anticancer activity. Culture media recirculates 
through the three inline chambers and an external reservoir, mimicking blood circulation and 
its residence times in the modelled organs. PBPK, physiologically based pharmacokinetic.
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Table 1
Assays in organs-on-chips
Biological process/feature Assay Refs
Cell growth and death
Proliferation 5-ethynyl-2′-deoxyuridine (EdU) labelling 56
Ki-67 immunostaining 33
Cell counting 44
Cell cycle Flow cytometry 42,44
Viability Alamar blue staining 39,55,60–62, 64,65,68,76
Live/dead 55,64,65,68
CellTiter-Blue* staining 60–62
CellTracker Green* and CellTrace Blue AM* staining 39
Apoptosis Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 38,43
Hoechst 33342 staining 43
Cell and tissue morphology
Myocyte elongation and alignment Phase contrast microscopy 47,48
Microfluorimetry 36,45–48
Epithelial polarity Microfluorimetry 55,56
Collagen fibre alignment Birefringence imaging 48,64
Intestinal villus crypt structure Scanning electron microscopy 56
Microfluorimetry 56
Tubulogenesis Phase contrast microscopy and microfluorimetry 73
Cardiac remodelling Reverse transcription PCR 47
Whole-transcript microarray 47
Cell differentiation and maturation
Epithelial–mesenchymal transition Microfluorimetry 37
Protein localization Microfluorimetry 56
Cardiomyocyte maturation Real-time quantitative PCR 48
Haematopoiesis Flow cytometry 40
Cell motility and contractility
2D migration Microfluorimetry 34
3D invasion and migration Phase contrast microscopy 68,71
Cell aggregation Microfluorimetry 34,68
Spheroid dispersion Microfluorimetry 37
Extravasation Microfluorimetry 13,33
Metastasis Microfluorimetry 33
Cardiac contractility Video microscopy 36,45–47
Barrier function
Permeability Transepithelial electrical resistance 15,55–57,62,81
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Biological process/feature Assay Refs
Reaction product fluorescence 56
Fluorescence 62
Microfluorimetry 56,62,81
Phase contrast microscopy 15
Mass spectroscopy 57
Intercellular junctions Microfluorimetry 13,15,55,71,81
Oxygen transport In-line fluorescent sensing 15
Nanoparticle translocation or uptake Microfluorimetry 13,81
Intracellular drug accumulation Microfluorimetry 39
Metabolism
Enzyme activity and drug metabolism Reaction product fluorescence 42–44,53–56




Gene expression Real-time quantitative PCR 44,53
Glucose synthesis Colourimetry 42
Mitochondrial dysfunction JC-1 mitochondrial membrane potential indicator dye 42
Secretion
Albumin synthesis ELISA 42
Mucus production Alcian blue staining 56
Electrophysiology
Myocyte activity Microelectrode arrays 46,48
Microfluorimetry 46,48
Neuron activity Microelectrode arrays 41
Oxidative stress
Reactive oxygen species production Microfluorimetry 13,15,35
*
Proprietary name of assay or dye.
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Table 2
Three-dimensional cell culture matrices and scaffolds for organs-on-chips
Matrix or scaffold Cells Application Refs
Collagen Lung cancer cells Epithelial–mesenchymal transition 37
Breast cancer cells Invasion 68
Breast cancer cells, bone-differentiated mesenchymal stem 
cells
Invasion, metastasis 33
Vascular endothelial cells, endothelial pericytes Tubulogenesis 73
Cardiomyocytes Cardiac contraction 48
Matrigel Hepatocytes, colon tumour cells Drug metabolism, anticancer activity 64,65
Hepatocytes, embryonic fibroblasts Aggregate formation 68
Fibrin Vascular endothelial cells, mesenchymal stem cells Vasculogenesis 104,105
Alginate Myeloblasts Drug metabolism, anticancer activity 64,65
Poly(lactide-co-glycolide) Oral squamous cell carcinoma Tumour angiogenesis, anticancer activity 106
Foamed polylactic acid Hepatocytes, brain cancer cells Anticancer activity 76
Poly(ethylene) glycol Hepatocytes Drug metabolism 43
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